Bausch + Lomb Corporation
BLCO · Price history
Price at last available close
$17.62
+$0.67 (+3.95%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Bausch + Lomb Corporation
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options.
How they make money
Bausch + Lomb generates revenue by developing, manufacturing, and marketing a comprehensive portfolio of eye health products. The company operates through three segments—Vision Care, Pharmaceuticals, and Surgical—selling contact lenses, lens care products, OTC eye drops, vitamins, and surgical equipment to eye care professionals, retailers, and healthcare institutions globally.
Products & services
Contact lenses, contact lens care products, over-the-counter eye drops, eye vitamins, and surgical medical devices and equipment for eye health.
Brands & revenue mix
Monthly planned replacement contact lens for astigmatic patients using MoistureSeal technology.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract manufacturers and raw material suppliers — The company relies on various third-party suppliers for raw materials, components, and contract manufacturing services for its medical devices and pharmaceutical products.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
24
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
26
Poor
Financial Strength
31
Business Quality / Moat
32
Management
6
Growth Quality
37
Risk / Durability
21
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
29
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
40/100
Building Historical Record
Model Score 40/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •High debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for BLCO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can BLCO maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can BLCO fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is BLCO's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for BLCO to reach sustainable profitability?
- •What future growth or profitability would be needed to justify BLCO's current valuation?
Essential Investment Snapshot
Wall Street Score
24
Opportunity Score
29
Market Cap
$6.29B
P/E Ratio
-35.5
EPS
$-0.48
52-Week High
$18.92
52-Week Low
$13.77
Beta
0.56
Analyst Target
$21.00
Shares Outstanding
353.8M
Total Revenue
$5.32B
Total Debt
$5.12B
Dividend
No current dividend
Liquidation Value / Share
$18.21
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for BLCO
Detected from reported data — verify before acting.High debt risk
Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative • Cash covers less than 20% of total debt
Community Sentiment
0 active · 0 total callsNo personal call yet on BLCO.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Broad global portfolio of eye health products.
- +Proprietary technology such as MoistureSeal.
Potential downside factors
- −Debt risk (high): Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Cash covers less than 20% of total debt.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
24
Sep 9, 2026
Change
+0.1
points
Current Score
24
Oct 1, 2026
Category Changes
BLCO increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
21
Projected Change
-2.8 points
Preliminary comparable-period financial changes suggest decline of approximately 2.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$17.62
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.32B | $5.10B | $4.79B | $4.15B | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $2.27B | $2.31B | $1.87B | $1.64B | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $3.04B | $2.79B | $2.92B | $2.50B | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $404.0M | $371.0M | $343.0M | $324.0M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $2.22B | $2.23B | $2.08B | $1.74B | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $2.66B | $2.60B | $2.76B | $2.37B | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $742.0M | $535.0M | $601.0M | $499.0M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $380.0M | $188.0M | $162.0M | $130.0M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $396.0M | $431.0M | $399.0M | $283.0M | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$65.0M | -$317.0M | -$234.0M | -$166.0M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $98.0M | $35.0M | $71.0M | $82.0M | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$171.0M | -$360.0M | -$317.0M | -$260.0M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.48 | $-1.02 | $-0.90 | $-0.74 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 357M | 354M | 352M | 351M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 357M | 354M | 352M | 351M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$1.39B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.04
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+3.1%
Cash Change
+34.9%
Margin Change
+3.8 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, cash levels, net income margin. Pressure indicators included EPS growth, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 8.7%. EPS declined 78.2%. Cash increased 34.9%. Total debt increased 3.1%. Net income margin improved by 3.8 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
56
Smart Money
56
Number of Gurus
3
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Instruments & SuppliesNews
Financial Survey: Merit Medical Systems (NASDAQ:MMSI) vs. Bausch + Lomb (NYSE:BLCO)
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
Rumor Mill · BLCO
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial